APPLICATION
ANDA210771
TYPE
ANDA
ORIGINAL APPROVAL
2023-03-20
LATEST ACTION
2023-03-20
ROUTE
ORAL
DOSAGE FORM
CAPSULE, EXTENDED RELEASE
MARKETING STATUS
Prescription
Products
LEVOMILNACIPRAN HYDROCHLORIDEPrescription
LEVOMILNACIPRAN HYDROCHLORIDE EQ 80MG BASE · CAPSULE, EXTENDED RELEASE · ORAL
LEVOMILNACIPRAN HYDROCHLORIDEPrescription
LEVOMILNACIPRAN HYDROCHLORIDE EQ 20MG BASE · CAPSULE, EXTENDED RELEASE · ORAL
LEVOMILNACIPRAN HYDROCHLORIDEPrescription
LEVOMILNACIPRAN HYDROCHLORIDE EQ 120MG BASE · CAPSULE, EXTENDED RELEASE · ORAL
LEVOMILNACIPRAN HYDROCHLORIDEPrescription
LEVOMILNACIPRAN HYDROCHLORIDE EQ 40MG BASE · CAPSULE, EXTENDED RELEASE · ORAL
Approval history
Source: FDA Drugs@FDA. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data, not medical, legal, or regulatory advice.
Weekly Briefing
Read a past issue →Get the Weekly GxP Briefing
Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.